<DOC>
	<DOCNO>NCT01632358</DOCNO>
	<brief_summary>The study ass safety , tolerability pharmacokinetics TAP311 patient dyslipidemia .</brief_summary>
	<brief_title>Safety Pharmacokinetis TAP311 Dyslipidemic Patients</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Male female patient 18 80 year ( inclusive ) age . Patients treat dyslipidemia medication HMGCoA reductase inhibitor ( statin ) least 4 week prior Day 1 . Patients stable dos current medication , , least 3 month eligible . Patients must weigh least 50 kg participate study , must body mass index ( BMI ) within range 18 40 kg/m2 . Use investigational drug time enrollment History hypersensitivity study drug drug similar chemical class Use lipid modifying agent ( e.g . fenofibrate , niacin , omega3 fatty acid , etc . ) statins exclude subject . Pregnant nursing ( lactate ) woman Diabetic patient whose plasma glucose well control stable diabetic treatment least 3 month Heavy smoker ( smoke 10 cigarette day routinely refrain smoke study ) . Women childbearing potential ( WOCBP ) include must use highly effective contraception Significant illness within two ( 2 ) week prior initial dose History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>